Related Experiment Video
Updated: Dec 28, 2025

Isolation of Culturable Yeasts and Molds from Soils to Investigate Fungal Population Structure
Published on: May 27, 2022
Uncovering New Mutations Conferring Azole Resistance in the Aspergillus fumigatus cyp51A Gene
Peiying Chen1, Musang Liu2,3, Qiuqiong Zeng1
1Department of Dermatology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China.
Abstract:
The opportunistic pathogen Aspergillus fumigatus has developed worldwide resistance to azoles largely through mutations in cytochromeP450 enzyme Cyp51. In this study, we indicated that in vitro azole situation results in emergence of azole-resistant mutations. There are previously identified azole-resistant cyp51A mutations (M220K, M220I, M220R, G54E and G54W mutations) and we successfully identified in this study two new mutations (N248K/V436A, Y433N substitution) conferring azole resistance among 18 independent stable azole-resistant isolates. The Galleria mellonella model of A. fumigatus infection experiment verified that Cyp51A mutations N248K/V436A and Y433N reduce efficacy of azole therapy. In addition, a predicted Cyp51A 3D structural model suggested that Y433N mutation causes the reduced affinities between drug target Cyp51A and azole antifungals. This study suggests that drug selection pressure make it possible to isolate unidentified cyp51A mutations conferring azole resistance in A. fumigatus.
Insights
Azole resistance in Aspergillus fumigatus emerges due to mutations in the Cyp51 enzyme. This study identified new mutations conferring resistance, impacting azole therapy efficacy.
Area of Science:
- Medical Mycology
- Antimicrobial Resistance
- Molecular Biology
Background:
- The opportunistic fungal pathogen *Aspergillus fumigatus* exhibits widespread azole resistance, primarily driven by mutations in the cytochrome P450 enzyme Cyp51.
- Azole antifungals are crucial for treating invasive aspergillosis, but rising resistance threatens their clinical utility.
Purpose of the Study:
- To investigate the emergence of azole resistance in *A. fumigatus* under *in vitro* azole selection pressure.
- To identify novel mutations in the *cyp51A* gene associated with azole resistance.
- To evaluate the impact of newly identified mutations on azole therapy efficacy *in vivo* and drug-target interactions.
Main Methods:
- Induction of azole resistance in *A. fumigatus* isolates through *in vitro* drug exposure.
- Sequencing of the *cyp51A* gene to identify mutations in resistant isolates.
- Assessment of azole therapy efficacy using the *Galleria mellonella* infection model.
- Computational modeling to predict the structural impact of mutations on Cyp51A-azole binding.
Main Results:
- *In vitro* azole treatment successfully induced azole-resistant *A. fumigatus* isolates.
- Eighteen independent stable azole-resistant isolates were obtained, revealing previously identified mutations (M220K, M220I, M220R, G54E, G54W) and two novel mutations (N248K/V436A, Y433N).
- The novel Cyp51A mutations N248K/V436A and Y433N were confirmed to reduce azole therapy efficacy in the *Galleria mellonella* model, with Y433N predicted to decrease drug-target binding affinity.
Conclusions:
- Drug selection pressure is a significant driver for the emergence of previously unidentified *cyp51A* mutations conferring azole resistance in *A. fumigatus*.
- The identified novel mutations (N248K/V436A, Y433N) contribute to azole resistance and reduced therapeutic efficacy.
- Understanding these resistance mechanisms is crucial for developing effective antifungal strategies against *A. fumigatus*.
Related Concept Videos
Mutations in Microorganisms
Fungal Phylum Ascomycota
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

